Key facts
- Kenai Therapeutics’s last known valuation is $110.0M.
- It has raised $86.8M; the latest was Early Stage VC ($81.8M) in Jun 2024.
- Notable investors include Euclidean Capital, Alaska Permanent Fund, California Institute for Regenerative Medicine, Cure Ventures, Saisei Ventures — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Kenai Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Kenai Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Kenai Therapeutics
Operator of a biotechnology company intended to cure neurological disease. The company offers off-the-shelf neuron replacement therapies as potent disease-modifying treatments for neurological disorders, enabling doctors with new-generation approaches for treating diseases like Parkinson's.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2022
- Employees
- 24
- Website
- kenaitx.com/
- Ownership
- Privately Held (backing)
Kenai Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Kenai Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Kenai Therapeutics in its N-PORT filings yet. We sweep new filings monthly.